These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 23173602)
1. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Clement F; Dewar V; Van Braeckel E; Desombere I; Dewerchin M; Swysen C; Demoitié MA; Jongert E; Cohen J; Leroux-Roels G; Cambron P Malar J; 2012 Nov; 11():384. PubMed ID: 23173602 [TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum. Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382 [TBL] [Abstract][Full Text] [Related]
3. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL Malar J; 2011 Sep; 10():266. PubMed ID: 21920045 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC). Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348 [TBL] [Abstract][Full Text] [Related]
5. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517 [TBL] [Abstract][Full Text] [Related]
6. Live attenuated rubella vectors expressing Plasmodium falciparum circumsporozoite protein (Pf-CSP) provide a novel malaria vaccine platform in the rhesus macaque. Virnik K; Zhou W; Medvedev A; Walsh G; Perry-Anderson J; Majam V; Felber BK; Kumar S; Berkower I Biochem Biophys Res Commun; 2021 Nov; 577():58-63. PubMed ID: 34507066 [TBL] [Abstract][Full Text] [Related]
7. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
9. A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines. Kostense S; Mommaas B; Hendriks J; Verhoeven M; Ter Haak M; Tirion F; Wiesken E; Pau MG; Radosevic K; Goudsmit J Clin Vaccine Immunol; 2011 May; 18(5):776-82. PubMed ID: 21411600 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237 [TBL] [Abstract][Full Text] [Related]
11. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of host humoral antibody production against Plasmodium falciparum recombinant circumsporozoite antigen in Nigerian children. Oluwasogo OA; Ebenezer OO; Chiaka A J Vector Borne Dis; 2012 Sep; 49(3):151-6. PubMed ID: 23135009 [TBL] [Abstract][Full Text] [Related]
13. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295 [TBL] [Abstract][Full Text] [Related]
14. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. John CC; Moormann AM; Pregibon DC; Sumba PO; McHugh MM; Narum DL; Lanar DE; Schluchter MD; Kazura JW Am J Trop Med Hyg; 2005 Jul; 73(1):222-8. PubMed ID: 16014863 [TBL] [Abstract][Full Text] [Related]
15. Synthetic Antigens Derived from Pratt-Riccio LR; De Souza Perce-Da-Silva D; Da Costa Lima-Junior J; Pratt Riccio EK; Ribeiro-Alves M; Santos F; Arruda M; Camus D; Druilhe P; Oliveira-Ferreira J; Daniel-Ribeiro CT; Banic DM Am J Trop Med Hyg; 2017 Nov; 97(5):1581-1592. PubMed ID: 29016339 [TBL] [Abstract][Full Text] [Related]
16. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021 [TBL] [Abstract][Full Text] [Related]
17. [Profiles of IgG responses against CSP, GLURP and LSA-3NR2 in urban malaria (Dakar): relations with haemoglobin levels and parasite densities]. Mbengue B; Kpodji P; Sylla Niang M; Varela ML; Thiam A; Sow A; Ndiaye K; Aidara M; Thiam F; Ndiaye R; Diop G; Nguer CM; Perraut R; Dièye A Bull Soc Pathol Exot; 2016 May; 109(2):91-8. PubMed ID: 27100862 [TBL] [Abstract][Full Text] [Related]
18. Structural basis for antibody recognition of the NANP repeats in Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum. Teo WH; Nurul AA; Norazmi MN Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846 [TBL] [Abstract][Full Text] [Related]
20. Malaria DNA vaccines in Aotus monkeys. Gramzinski RA; Maris DC; Doolan D; Charoenvit Y; Obaldia N; Rossan R; Sedegah M; Wang R; Hobart P; Margalith M; Hoffman S Vaccine; 1997 Jun; 15(8):913-5. PubMed ID: 9234546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]